Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 1.915 USD 2.41%
Market Cap: 137.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+29%
Revenue
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZNTL is 6.311 USD with a low forecast of 2.525 USD and a high forecast of 10.5 USD.

ZNTL Lowest Forecast
Wall Street Target
2.525 USD
32% Upside
ZNTL Average Forecast
Wall Street Target
6.311 USD
230% Upside
ZNTL Highest Forecast
Wall Street Target
10.5 USD
448% Upside
Lowest
Price Target
2.525 USD
32% Upside
Average
Price Target
6.311 USD
230% Upside
Highest
Price Target
10.5 USD
448% Upside
Zentalis Pharmaceuticals Inc Competitors:
Price Targets
688687
Beijing Kawin Technology Share-holding Co Ltd
31% Upside
IKT
Inhibikase Therapeutics Inc
386% Upside
688235
Beigene Ltd
30% Upside
ORY
Oryzon Genomics SA
179% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
31% Upside
IKT
Inhibikase Therapeutics Inc
386% Upside
688235
Beigene Ltd
30% Upside
ORY
Oryzon Genomics SA
179% Upside
300676
BGI Genomics Co Ltd
0% Downside
M
MGX
Metagenomi Inc
468% Upside
REGN
Regeneron Pharmaceuticals Inc
26% Upside
P
000403
Pacific Shuanglin Bio pharmacy Co Ltd
20% Upside

Revenue
Forecast

Revenue Estimate
Zentalis Pharmaceuticals Inc

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -47%.

N/A
Past Growth
-47%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zentalis Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

See Also

Summary
ZNTL intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZNTL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZNTL stock valuation using valuation multiples.
Wall Street Estimates
ZNTL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZNTL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZNTL's stock price target?
Price Target
6.311 USD

According to Wall Street analysts, the average 1-year price target for ZNTL is 6.311 USD with a low forecast of 2.525 USD and a high forecast of 10.5 USD.

What is Zentalis Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
-47%

The compound annual growth rate of Zentalis Pharmaceuticals Inc's revenue for the next 3 years is -47%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 276,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.